This study was designed to assess evidence for an association between the treatment of gastroesophageal reflux disease (GERD) with proton pump inhibitors (PPIs) and improvement in obstructive sleep apnea (OSA). We conducted a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies to evaluate the treatment effect of PPIs on OSA symptoms and indices in patients with GERD. EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov were reviewed up to October 2014. From 238 articles, two randomized trials and four prospective cohort studies were selected. In four cohort studies there were no differences in the apnea-hypopnea indices before and after treatment with PPIs (standard mean difference, 0.21; 95% confidence interval, -0.11 to 0.54). There was moderate heterogeneity among these studies. Two cohort studies revealed significantly decreased apnea indices after treatment (percent change, 31% and 35%), but one showed no significant difference. A significant improvement in the Epworth Sleepiness Scale was observed in three cohort studies and one trial. The frequency of apnea attacks recorded in diaries was decreased by 73% in one trial. In conclusion, available studies do not provide enough evidence to make firm conclusions about the effects of PPI treatment on OSA symptoms and indices in patients with concomitant GERD. Controlled clinical trials with larger sample sizes are needed to evaluate these associations. We recommend PPIs in OSA patients with concomitant GERD to treat reflux symptoms. This treatment may improve the quality of sleep without any effect on apnea-hypopnea indices.
T he prevalence of gastroesophageal refl ux disease (GERD) is signifi cantly higher in patients with obstructive sleep apnea (OSA) (1) (2) (3) (4) (5) (6) , and 54% to 76% of patients with OSA have GERD (2, 3) . Th ese two conditions share one common risk factor, namely obesity, which increases the risk for both apnea and refl ux (7) . Th is association may be explained by lower esophageal sphincter pressures and prolonged esophageal relaxation following swallowing (8) . Th ese changes could increase the frequency and severity of refl ux. Nocturnal refl ux could cause sleep arousals and sleep fragmentation in OSA patients, and acid exposure could cause edema and infl ammation in the upper airway, which increase the frequency of airway occlusions during inspiration (6) . Studies supporting this hypothesis have shown that continuous positive airway pressure (CPAP) has antirefl ux eff ects in OSA patients (9, 10) . However, other studies have reported that the severity of OSA does not correlate with the occurrence of refl ux symptoms (11) . Given the signifi cant morbidity and mortality of OSA, including left ventricular dysfunction, arrhythmias, myocardial infarction, stroke, systemic hypertension, and risk of motor vehicle accidents, it is important to evaluate all factors associated with OSA and to consider the potential benefi t of treatment of factors not directly related to upper airway anatomy (12) (13) (14) (15) . Several studies have suggested that proton pump inhibitors (PPIs) improve OSA symptoms and reduce some complications. We conducted a systematic review and meta-analysis of the published reports to better understand the treatment eff ect of GERD on the OSA-hypopnea syndrome.
METHODS
We searched EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov from database inception to October 2014. We used the following text words as search terms: "sleep apnea syndrome" and "proton pump inhibitor." Our search included articles published in English and non-English languages. We also scanned the bibliographies of all retrieved articles for additional relevant articles.
Two independent reviewers (S.R. and S.K.) performed article selection, data extraction, and assessment of the risk of bias. Disagreements were resolved through consensus. Studies were included if they met the following criteria: 1) were controlled clinical trials or observational studies that assessed the eff ect of PPIs on OSA, including symptoms of daytime somnolence, nocturnal symptoms, Epworth Sleepiness Score (ESS), apnea-hypopnea index (AHI), apnea index, hypopnea index, and respiratory disturbance index; 2) reported concomitant GERD in patients with OSA; and 3) provided adequate data to extract the outcomes. We excluded studies that reported only the prevalence of GERD in OSA patients, patients who were treated with CPAP and PPIs, and OSA patients without underlying GERD who were treated with PPIs. If multiple updates of the same data were found, we used the most recent version for analysis. From each study, we abstracted the study design, setting, population characteristics (including sex, age, race or ethnicity, baseline body mass index [BMI] , and baseline AHI), patient eligibility and exclusion criteria, number of patients, type of PPIs used, treatment duration, and method of outcome determination.
Two reviewers (S.R. and S.K.) independently assessed the quality of each trial by using a tool developed by the Cochrane Collaboration (16) . Each trial was given an overall summary assessment of low, unclear, or high risk of bias. We adapted existing tools to assess the quality of observational studies. Th e strength of evidence for outcomes was graded as high, moderate, low, or very low according to the approach of the GRADE working group (17) .
AHIs in patients before treatment versus after treatment were evaluated. Statistical analysis was conducted with Review Manager (RevMan Version 5.3, Th e Cochrane Collaboration, Th e Nordic Cochrane Centre, Copenhagen, Denmark). Th e chi-square test and I 2 statistic were used to address heterogeneity among studies. Th e results of the studies were pooled, and an overall standard mean diff erence with 95% confi dence intervals (CIs) was obtained using generic inverse variance weighting and a random eff ects method.
RESULTS
Th e electronic and manual searches yielded 238 total citations (Figure 1 ). We identifi ed 20 potentially relevant full-text articles and analyzed six published articles, published as full papers, which met our inclusion criteria. No additional abstracts were identifi ed by hand searches of conference proceedings.
Two controlled clinical trials compared the eff ects of PPIs and placebos on OSA (18, 19) . Th e fi rst trial was a double-blind, randomized, placebo-controlled crossover trial (18) . Th is trial recruited 57 patients with ESS > 8 (mean ESS ± SD: 14 ± 3.5), mild to moderate OSA (mean AHI ± SD: 10 ± 8.4), and typical symptoms and fi nding of GERD between February 2004 and August 2006 and treated them with either placebo or pantoprazole 40 mg once daily followed by a 2-week washout period and then a 2-week crossover treatment period. ESS decreased with pantoprazole (-1.8, 95% CI: -3.0 to -0.5) compared with placebo (-1.5, 95% CI: -2.1 to -0.4, P = 0.04). Th ere were no signifi cant changes in sleep-related quality of life using the Functional Outcomes Sleep Questionnaire or reaction times, tested by having subjects push a button as fast as they could whenever they saw a clock begin counting up from 0000 (18) . Th e trial had a low risk of bias.
Th e second trial included 20 patients with confi rmed OSA (mean AHI: 30.9) by overnight polysomnography and confi rmed GERD by 24 h esophageal pH electrode (19) . Th e patients were randomly divided into two groups and treated with omeprazole 20 mg or placebo 30 minutes before breakfast and before dinner (n = 10 each group) for 6 weeks. Th e number of apnea attacks, which were defi ned as a symptom of nocturnal choking, gasping, or snoring that awakened the patients, was recorded by patients in diaries. Th e frequency of apnea attacks decreased 73% in the treatment group compared to their basal period and in the treatment group compared with the placebo group in the sixth week (P < 0.001). Th is trial had an unclear risk of bias due to unclear reporting of randomization and allocation concealment techniques.
Th e four prospective cohort studies analyzed in this review included 91 patients who had OSA and GERD. Th e main characteristics of these studies are summarized in Table 1 . Four studies (20) (21) (22) (23) reported data on AHI; three studies (20, 21, 23) provided data on apnea index, and three studies (20, 22) reported data on ESS. Th ese trials had methodological limitations that led to an unclear risk of bias since all studies were single-center prospective cohort studies conducted in the United States, used patients' baseline parameters as the control, and had small sample sizes. Four observational studies compared the eff ects of PPI use on AHI in patients before treatment versus after treatment (20) (21) (22) (23) . Th ere was no statistically signifi cant diff erence between the two groups. Th e standard mean diff erence was 0.21 (95% CI: -0.11 to 0.54) ( Table 2 ). Heterogeneity was minimal in the studies (P for heterogeneity = 0.31, I 2 = 17%).
Th ree observational studies (20, 21, 23) compared the eff ects of PPI use on the apnea index in patients before treatment versus after treatment. Two studies reported a statistically signifi cant improvement in the apnea
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index (mean 5.9 ± 7.2 to 3.8 ± 4.7, P = 0.04 in the study by Friedman [20] ; mean 45 [range: ] to 31 [range: 1-78], P = 0.04 in the study by Senior [23] ). However, the study reported by Steward revealed no statistically signifi cant diff erence between the two groups (mean change 1.4, 95% CI: -0.1 to 2.9, P = 0.07) (21) . No baseline mean apnea index in this study was available. Th ree observational studies (20) (21) (22) compared the eff ects of PPI use on ESS in patients before treatment versus after treatment. Two studies reported statistically signifi cant improvement of ESS and provided numerical scores for the ESS before and after treatment (Figure 2) . One study reported a statistically signifi cant mean change in ESS (21) . Two studies reported decreased snoring as assessed by bed partners (20, 21) , and one reported decreased upper airway infl ammation based on fi beroptic nasopharyngoscopy examinations before and after treatment (22) .
DISCUSSION
Th e articles used in this systematic review and meta-analysis studied the eff ects of PPIs on OSA indices, daytime sleepiness, and other nocturnal symptoms. Th is analysis included two randomized controlled trials and four observational prospective studies. Th e studies identifi ed a modest benefi t of PPI therapy on daytime somnolence but did not identify any signifi cant diff erence in apnea or hypopnea indices. Th e eff ect on the ESS was modest and not associated with any change in sleep-related quality of life or reaction times. Th e other trial reported a reduction in nocturnal symptoms based on diary records. Th e symptoms are not necessarily unique to OSA and could have other causes during the night. Th e results with AHI comparisons should be interpreted with caution, due to the clinical heterogeneity among studies and unclear risk of bias. Th ese limitations are discussed more below.
Th ere are several potential explanations for the lack of benefi t with PPI therapy in patients with OSA. GERD and OSA are relatively common problems; they could occur coincidentally in some patients and have no causal relationships. Shepherd and coworkers reported detailed studies in eight patients with OSA undergoing polysomnography with esophageal manometry and pH monitoring (8) . During the recording phase without CPAP, the patients had 70 ± 39 respiratory events per hour and 2.7 ± 1.8 refl ux events per hour. Th e number of obstructive events in this study appeared to have little or no eff ect on refl ux events. In addition, overlapping symptoms could confuse this situation and an y conclusions about cause and eff ect relationships. However, very frequent refl ux events could infl uence OSA and sleep quality through central nervous system arousals, chronic lower esophageal infl ammation with vagal stimulation, and laryngeal infl ammation with changes in the upper airway dynamics.
Th ere might be a threshold in the number of refl ux events required before any eff ect occurs, and the duration of these two syndromes could infl uence any interaction. Th e treatment of GERD with PPIs may require more time than most studies have used in their study design. An adequate treatment period for PPIs to completely resolve anatomic changes caused by acid refl ux-related injury can take up to 6 months; however, only one study in this review reached that period of time (20, 24, 25) . Another possibility is that PPI treatment may truly improve Effect of proton pump inhibitors on obstructive sleep apnea symptoms and indices in patients with GERD January 2016 OSA symptoms, but this eff ect would be important only in patients with very frequent refl ux events. In addition, treatment with CPAP could have several possible eff ects on GERD which might infl uence results in studies on GERD in patients with OSA. First, CPAP may have no eff ect, or CPAP could change intrathoracic pressure dynamics and reduce refl ux. Th is eff ect most likely would occur at the gastroesophageal junction. CPAP could also change esophageal motility and improve esophageal clearance. Shepherd reported that CPAP increased the nadir pressure in the lower esophagus and reduced the duration of the lower esophageal sphincter relaxation time (8) . Again, these eff ects are important only in patients with frequent refl ux events.
Our meta-analysis has several limitations. First, our analysis included only six studies with small numbers of patients. Second, there was heterogeneity across the studies in the analysis of AHI reduction. Th is can be partly explained by diff erent study designs, types of PPIs, and duration of treatment. Most studies had design limitations, including small sample size and single-center cohort studies, which resulted in a low strength of evidence. Observational studies that used patients' baseline parameters as controls may be compromised by placebo eff ects in addition to other design limitations. Th e ESS is a self-assessment scale that represents only a predilection to fall asleep and is not a specifi c outcome in OSA patients. Other symptoms reported in sleep diaries may not be specifi c for OSA and may introduce another source of variability in study results. Patients with GERD have reduced health-related quality of life, and this is associated with nocturnal refl ux symptoms (26, 27) . We used a random eff ects method for analysis to account for heterogeneity among studies, and we attempted to minimize the risk of missing relevant studies by searching multiple databases, bibliographies, and trial registries.
